硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立  

Establishment of a bortezomib-resistant cell line KM3/BTZ of human multiple myeloma

作　　者：蒲业迪[1] 李丽珍[1] 马道新[1] 董珂[1] 赵川莉[1] 宋强[1] 王鲁群[1] 

机构地区：[1]山东大学齐鲁医院血液科,济南250012

出　　处：《山东大学学报（医学版）》2013年第2期33-36,43,共5页Journal of Shandong University:Health Sciences

基　　金：山东省科技攻关课题基金(2008GG10002049)

摘　　要：目的建立人多发性骨髓瘤耐硼替佐米的细胞株,并对其生物学特性及耐药机制进行初步探讨。方法采用浓度梯度递增法,以人多发性骨髓瘤KM3细胞株为亲本,建立耐硼替佐米的多发性骨髓瘤细胞株,绘制生长曲线,并计算倍增时间;MTT法鉴定耐药细胞株的耐药性;RT-PCR方法检测MDR-1在亲代和耐药细胞株中的表达情况。结果成功建立耐硼替佐米的多发性骨髓瘤细胞株KM3/BTZ,耐药倍数为19.7倍。与亲代细胞相比,耐药细胞株倍增时间延长(P<0.05)。多药耐药相关基因MDR-1未参与耐药性的发生。结论成功建立人多发性骨髓瘤耐药细胞株KM3/BTZ,耐药性稳定,为研究耐药机制及逆转耐药提供了理想的模型。Objective To establish a bortezomib-resistant cell line KM3/BTZ of human multiple myeloma （MM） and investigate its biological characteristics and mechanisms of drug-resistant in MM preliminarily. Methods The KM3 cell line was exposured to bortezomib at increasing doses to obtain a stable bortezomib-resistant KM3/BTZ in vitro. The growth curve was drawn and the doubling time was counted. MTT assay was used to evaluate the sensitivity of drug resistance. The expression of MDR-1 mRNA was determined by RT-PCR in KM3 and KM3/BTZ cell lines. Results The KM3/BTZ cell line resistant to bortezomib was established successfully with the resistance index of 19.7 （ KM3/ BTZ to KM3 ）. Compared with the parent cells, KM3/BTZ exhibited a significant longer doubling time （P 〈 0.05 ） . The expression of MDR-1 mRNA was not observed in either resistant or parent cells. Conclusion We have successfully established bortezomib resistance cell line KM3/BTZ and its drug-resistant character is stable. The KM3/BTZ cell line might serve as an ideal model to explore the drug-resistance mechanisms and to reverse the drug resistance.

关 键 词：硼替佐米 耐药 多发性骨髓瘤 细胞株 

分 类 号：R733.3[医药卫生—肿瘤]